Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Multicenter Trial For Patients With Acute Crohn's Disease

This study has been completed.
Information provided by (Responsible Party):
Teva Pharmaceutical Industries ( Teva Branded Pharmaceutical Products, R&D Inc. ) Identifier:
First received: May 3, 2002
Last updated: February 20, 2013
Last verified: February 2013
The purpose of this study is to see if etiprednol dicloacetate is safe and effective for the treatment of acute Crohn's disease.

Condition Intervention Phase
Crohn's Disease
Drug: etiprednol dicloacetate
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Teva Pharmaceutical Industries:

Study Start Date: January 2002
Study Completion Date: January 2004
Primary Completion Date: January 2004 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
  • Must have active confirmed Crohn's disease with CDAI > 220 and < 400.
  • Otherwise healthy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00035503

United States, California
Stuart Weisman
Palo Alto, California, United States, 94304
United States, Colorado
University of Colorado Medical Center
Denver, Colorado, United States, 80262
United States, District of Columbia
Washington Hospital Center
Washington, District of Columbia, United States, 20010
United States, Florida
Mark Lamet
Hollywood, Florida, United States, 33021
Wayne Schonfeld
Hollywood, Florida, United States, 33021
Mount Sinai Medical Center
Miami Beach, Florida, United States, 33140
United States, Illinois
University of Chicago Hospital Medical Center
Chicago, Illinois, United States, 60637
United States, Kentucky
Gerald Dryden
Louisville, Kentucky, United States, 40202
United States, New York
Richard MacDermott
Albany, New York, United States, 12208
Canada, Ontario
Hillary Steinhart
Toronto, Ontario, Canada, M5G 1XB
Canada, Quebec
Gary Wild
Montreal, Quebec, Canada, H3G 1A4
Sponsors and Collaborators
Teva Branded Pharmaceutical Products, R&D Inc.
  More Information

Responsible Party: Teva Branded Pharmaceutical Products, R&D Inc. Identifier: NCT00035503     History of Changes
Other Study ID Numbers: IXR-201-19-166
Study First Received: May 3, 2002
Last Updated: February 20, 2013

Additional relevant MeSH terms:
Crohn Disease
Inflammatory Bowel Diseases
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases processed this record on May 23, 2017